Shares slid 7.7% to $32.22 as the aftershocks from Ideaya Biosciences' massive discounted stock sale continue rippling through the trading floor, leaving investors to weigh fresh capital against a meaningfully larger share count.
The Offering Landed Bigger Than Advertised — And at a Steep Discount. The company sold 5,555,556 shares and pre-funded warrants for another 5,555,576 shares at $27.00 per share — a roughly 4.6% discount to the $28.29 last sale price the day before the deal was announced. Underwriters fully exercised their option for 1,666,669 extra shares, pushing total gross proceeds to approximately $345 million. That means the final deal dumped roughly 12.8 million new shares into a stock that had only 87.9 million shares outstanding as of March 31. In plain terms, existing owners saw their slice of the company shrink by about 14–15% overnight.
The Stock Rallied Into the Deal — Then Gave It All Back. Ideaya's stock had climbed about 13% in the prior week on strong data at the ASCO oncology conference, so the offering came right after a rally, hitting investors who bought the run-up hardest.
Analysts turned more cautious afterward, trimming 2026 revenue forecasts and raising projected losses per share. The stock bottomed near $27 around the deal's close on June 10, recovered to $34.91 by June 23, and is now slipping again — a pattern suggesting the market hasn't fully digested the new supply.
The Cash Buys Runway for Three Cancer Programs at Once. The $300 million provides capital to advance all three programs concurrently — its lead drug darovasertib through potential U.S. commercial readiness, a lung-cancer antibody-drug treatment through expanded trials, and a third therapy into combination studies.
The company anticipates filing for FDA approval for its lead eye-cancer drug in the second half of 2026, making this not a desperation raise. One analysis called it "the clearest example of raising from strength."
Analysts Still See Upside — But the Bar Is Higher Now. Eighteen analysts rate the stock a "Strong Buy" with an average 12-month target of $51.69, implying 64% upside. Yet with more shares in the denominator, every future earnings milestone must now clear a higher per-share hurdle. Ideaya's profitability rank sits at just 1 out of 10, a reminder that clinical promise and actual profit remain very far apart. The stock's path from here hinges entirely on whether drug approvals arrive before the cash runs out.